Century Therapeutics, Inc. (NASDAQ: IPSC) experienced a significant decrease in its short interest during the month of August, according to recent data. As of August 31st, the total number of shares on short interest was 642,200, marking a decline of 14.0% from the previous total of 747,100 shares on August 15th. The current days-to-cover ratio is estimated at 6.4 days based on the average daily trading volume of 100,600 shares. Approximately 2.7% of Century Therapeutics’ shares are being sold short.
Several analyst reports have focused on IPSC in recent times. For instance, Chardan Capital lowered their price target for Century Therapeutics’ shares from $19.00 to $17.00 and maintained a “buy” rating on the stock in a research report published on Wednesday, August 9th. Additionally, Piper Sandler also reduced their price target from $14.00 to $10.00 and assigned an “overweight” rating to Century Therapeutics in another research report on Thursday, August 10th.
HC Wainwright followed suit by lowering their price target from $17.00 to $13.00 while maintaining a “buy” rating for the company in their research report released on Thursday, August 10th. Furthermore, JPMorgan Chase & Co., downgraded Century Therapeutics’ rating from “overweight” to “neutral” and slashed their target price for the stock from $28.00 to $5.00 as indicated in a report dated Monday, August 28th.
Despite these mixed analyst reports, Bloomberg.com data reveals that Century Therapeutics currently holds an overall consensus rating of “Moderate Buy,” with an average price target of $15.33 derived from multiple analysts.
Century Therapeutics focuses on developing innovative allogeneic cell therapies primarily designed to treat solid tumors and hematological malignancies. The company’s primary product candidate is CNTY-101, an allogeneic therapy generated from induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cells. CNTY-101 targets CD19 for patients with relapsed and refractory B-cell lymphoma.
In terms of shareholder activity, notable institutional investors have made adjustments to their stakes in Century Therapeutics lately. BlackRock Inc., for example, increased its position in the company by 14.4% during the second quarter, resulting in ownership of 1,615,174 shares valued at approximately $5,104,000. Vanguard Group Inc. also raised its stake by 17.8% during the third quarter and now holds 1,068,688 shares of Century Therapeutics’ stock estimated at $10,569,000. State Street Corp witnessed a growth of approximately 23.3% in its ownership during the second quarter and currently owns 454,791 shares worth $1,437,000. Lastly, Geode Capital Management LLC reported an increase of 5.3% in its holdings during the fourth quarter and now possesses 443,499 shares valued at $1,401,000.
Overall, IPSC has experienced a decline in short interest while receiving mixed ratings from analysts regarding its price target. Nevertheless, it continues to attract interest from institutional investors who have made adjustments to their stakes in the company as they see potential in Century Therapeutics’ transformative allogeneic cell therapies for solid tumor and hematological malignancy treatment.
Note: This article is created on September 19th based on the given data; therefore all statements should be attributed solely to that period.
Greif, Inc.
GEF
Buy
Updated on: 19/09/2023
Financial Health
Healthy
Debt to equity ratio: Strong Buy
Price to earnings ratio: Buy
Price to book ratio: Buy
DCF: Strong Buy
ROE: Neutral
Unleashing the Potential of IPSC: Century Therapeutics’ Impact on Cell Therapy
September 19, 2023 – Century Therapeutics, Inc: Evaluating the Potential of IPSC as an Allogeneic Cell Therapy
Century Therapeutics, Inc., a biotechnology company known for its cutting-edge research in the field of cell therapy, has been making waves with its latest research report on induced pluripotent stem cells (IPSCs). These transformative allogeneic cell therapies have shown great promise in the treatment of solid tumors and hematological malignancies.
One of Century Therapeutics’ most promising products is their lead candidate, CNTY-101. This therapy utilizes allogeneic IPSCs to develop chimeric antigen receptors (CAR)-iNK cells that target CD19 in relapsed and refractory B-cell lymphoma. By harnessing the power of IPSCs, Century Therapeutics aims to provide a novel approach to treating this challenging disease.
Currently, the market for IPSC therapy is gaining traction, especially as investors closely monitor the performance of companies like Century Therapeutics. On Tuesday, IPSC opened at $2.24 per share. The business’s 50-day moving average price stands at $2.72, while its two-hundred day moving average price is reported to be $3.14. It is important to note that the stock has seen some fluctuations over the past year, with a 1-year low of $2.20 and a high of $11.95.
Moreover, recent earnings reports highlight Century Therapeutics’ financial standing. In the last release on August 9th, the company reported an EPS of ($0.56) for the quarter, slightly below expectations by ($0.02). While revenue for this period stood at $0.10 million compared to an estimated $1.54 million by analysts. It should be noted that negative net margin was observed at 2,782.34% along with a negative return on equity of 43.88%.
Analysts are keeping a close eye on Century Therapeutics’ projected EPS for the year, estimated to be at -2.02. This figure is indicative of both the potential challenges faced by the company, as well as its ambitions to provide innovative solutions in the field of cell therapy.
In conclusion, Century Therapeutics, Inc. continues to forge ahead in its research and development efforts focused on IPSC therapy. With their leading product candidate CNTY-101 showing promising results in the treatment of B-cell lymphoma, investors and industry experts alike remain eager to witness the future advancements this biotechnology company has in store.
Please note: The information contained herein is based on current market trends and data available at the time of writing.
Discussion about this post